ISEE IVERIC bio Inc.

3.4
-0.09  -3%
Previous Close 3.49
Open 3.48
Price To Book 1.39
Market Cap 141,023,228
Shares 41,477,420
Volume 685,917
Short Ratio
Av. Daily Volume 1,758,640
Stock charts supplied by TradingView

NewsSee all news

  1. IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company's common stock. In addition, on

  2. IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019

    - Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2019 financial and operating results on Tuesday,

  3. IVERIC bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    - Overall Data Suggest a Dose Response Relationship Across Treatment Groups - - Conference Call and Webcast Today, October 28, 2019 at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced initial topline

  4. IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3rd Annual Genetic

  5. IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 2H 2020.
Zimura
Autosomal Recessive Stargardt Disease
Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated.
Zimura
Wet age-related macular degeneration (Wet-AMD)
Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met.
Fovista
Wet age-related macular degeneration (Wet-AMD)
Phase 2b data released October 28, 2019 met primary endpoint.
Zimura
Geographic atrophy
Phase 1/2 trial to be initiated 1H 2021.
IC-200
BEST1 related retinal diseases
Phase 1/2 trial to be initiated 2H 2020.
IC-100
Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP)

Latest News

  1. IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    IVERIC bio, Inc. (NASDAQ:ISEE) today reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company's common stock. In addition, on

  2. IVERIC bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12, 2019

    - Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2019 financial and operating results on Tuesday,

  3. IVERIC bio's Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    - Overall Data Suggest a Dose Response Relationship Across Treatment Groups - - Conference Call and Webcast Today, October 28, 2019 at 8:00 a.m. ET - IVERIC bio, Inc. (NASDAQ:ISEE) today announced initial topline

  4. IVERIC bio to Present at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3rd Annual Genetic

  5. IVERIC bio to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    IVERIC bio, Inc. (NASDAQ:ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio, will present an overview of the Company at the Ladenburg Thalmann 2019 Healthcare Conference in New York on